Kenvue Inc.
Rank #198ValueKVUE · NYSE · Consumer Defensive
Kenvue Inc. (KVUE) — Rank #198 by gross profitability (GP/assets 0.33) · ROE 13.9% · Piotroski F-Score N/A.
As-of 2026-09-15 · CIK 0001944048 · all metrics point-in-time as of the filing date.
About
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America.
Show moreShow less
It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc.
was incorporated in 2022 and is headquartered in Summit, New Jersey.
- Industry
- Household & Personal Products
- Sector
- Consumer Defensive
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- January 3
- Website
- kenvue.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-28filed 2026-02-20 | 2024-12-29filed 2025-02-24 | 2023-12-31filed 2024-03-01 | 2023-01-01filed 2024-03-01 |
|---|---|---|---|---|
| Revenue | 15,124.0 | 15,455.0 | 15,444.0 | 14,950.0 |
| Revenue growth (YoY) | -2.1% | 0.1% | 3.3% | 3.3% |
| Cost of revenue | 6,332.0 | 6,496.0 | 6,801.0 | 6,665.0 |
| Gross profit | 8,792.0 | 8,959.0 | 8,643.0 | 8,643.0 |
| Gross margin | 58.1% | 58.0% | 56.0% | 56.0% |
| Selling, general & administrative | 6,088.0 | 6,329.0 | 6,141.0 | 5,633.0 |
| Research & development | 382.0 | 408.0 | 399.0 | 375.0 |
| Operating income | 2,414.0 | 1,841.0 | 2,512.0 | 2,675.0 |
| Operating margin | 16.0% | 11.9% | 16.3% | 16.3% |
| Interest expense | — | — | 250.0 | 0.0 |
| Pre-tax income | 1,999.0 | 1,415.0 | 2,190.0 | 2,637.0 |
| Income tax expense | 529.0 | 385.0 | 526.0 | 573.0 |
| Net income | 1,470.0 | 1,030.0 | 1,664.0 | 2,064.0 |
| Net margin | 9.7% | 6.7% | 10.8% | 10.8% |
| EPS (basic) | $0.77 | $0.54 | $0.90 | $1.20 |
| EPS (diluted) | $0.76 | $0.54 | $0.90 | $1.20 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?